W. Von Schedit
1 Papers
W. Von Schedit is an academic researcher. The author has contributed to research in topics: Pexelizumab & Percutaneous coronary intervention. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial
Paul W. Armstrong,N. Bett,David Brieger,D. Chew,R. Dick,A. Farshid,P Garrahy,B. Gunalingham,R. Hendriks,John D. Horowitz,Nigel Jepson,Jeffrey Lefkovits,S. Lo,Ian T. Meredith,G. Nelson,G. New,Ananth M. Prasan,J. Rankin,P. Thompson,S. Worthley,R. Yadav,Kurt Huber,Gerald Maurer,P. Siostrzonek,J. Boland,C. Covens,Walter Desmet,K. Dujardin,M. Vrolix,Christopher E. Buller,P. Klinke,C. Lazzam,Sohrab Lutchmedial,Mina Madan,Madhu K. Natarajan,François Reeves,J. Rodes Cabau,Barry Rose,Erick Schampaert,Pierre Theroux,Mouhieddin Traboulsi,John G. Webb,Robert C. Welsh,R. Zimmerman,M. Aschermann,M. Branny,T. Budesinsky,P. Cervinka,H. Frantisek,T. Frantisek,L. Groch,P. Kala,M. Ritcher,R. Rokyta,J. St'asek,R. Stipal,I. Varvarovsky,D. Zamanek,M. Zelizko,T. Toftegaard Nielsen,K. Rasmussen,P. RiisHansen,P. Thayssen,P. Beaufils,P. Geslin,Y. Gottwalles,H. Lebreton,H. LeMarec,Gilles Montalescot,G. Roul,Phillippe Gabriel Steg,C. Tronc,H. J. Berger,Martin Borggrefe,J. Brachmann,P. Braun,M. Buerke,H. R. Figulla,H. Guelker,G. Hasenfuss,T. Heitzer,Hubertus Heuer,E. Hoffman,S. Hoffmann,K. H. Kuck,Franz-Josef Neumann,J. Neuzner,M. Rau,G. Richardt,Heribert Schunkert,R. Stern,W. Von Schedit,P. C. Werner,R. Zahn,G. Binetti,E. Bramucci,G. Carosio,A. Manari,A. Marzocchi,M. Medda,G. Piovaccari,Alessandro Politi,L. Vignali,R. Violini,M. Zanchetta,R. Zanini,K. Marques,H. Otto Peels,T. Slagboom,P. C. Smits,Harry Suryapranata,M. J. Suttorp,M. Van-DerEnt,I. Crozier,G. Devlin,Sian E. Harding,Harvey D. White,G. Wilkins,M. Krzeminska-Pakula,K. Loboz-Grudzien,W. Ruźyllo,W. Tracz,M. Trusz-Gluza,M. Almeida,J. Correiada Cunha,P. Farto Abreu,L. Mourão,H. Pereira,L. Providencia,R. Vascoda Gama,A. Bertriu,C. Cuellas,E. Esplugas,E. Garcia Fernandez,X. Goicolea,J. M. Hernandez,C. Macaya,V. Mainar,Angel Martínez Sánchez,P. Erikksson,Stefan James,G. Olivercrona,C. M. Pripp,E. Camenzind,M Pfisterer,M. Pieper,Hans Rickli,R. Acheatel,A. Ahmad,A. Albirini,R. Allen,A. Amkieh,H. V. Anderson,J. Anderson,B. Armstrong,W. Asfour,T. Ayres,M. Azrin,Z. Baber,L. Barr,G. Barsness,J. Batty,Mahesh Bikkina,James C. Blankenship,Duncan J. Campbell,P. Caples,T. Carlson,John C. Chambers,H. Chandna,B. Cheek,J. Cheirif,A. Chu,H. Colfer,B. Crenshaw,S. David,A. DeFranco,J. Dehoya,J. Diez,G. Eaton,E. Eichhorn,M. El Shahawy,T. Farah,W. Felten,D. Fortuin,Malcolm T. Foster,D. S. Gantt,J. Gard,M. Ghali,R. Glaser,M. Greenberg,John H. Griffin,G. Hanovich,N. Hassinger,S. Heifetz,Timothy D. Henry,J. Hermiller,J. Hernandez,R. Hodson,M. Imburgia,B. Iteld,Z. Jafar,A. Jain,N. Jamal,G. Kang,Ronald P. Karlsberg,S. Khanal,S. Khoury,J. Kieval,Robert Kipperman,Robert Kipperman,B. Kluck,David F. Kong,E. Kosinski,M. Kozak,H. Kozman,P. Kraft,A. Labroo,P. Lai,N. Lakkis,G. Lane,B. Laretta,D. Lee,M. Leesar,J. Leggett,M. Levine,S. Lieberman,M. Lim,J. Luber,V. Marques,K. Marzo,J. McGarvey,G. McKendall,B. McLellan,M. Meengs,D. Mego,A. Mehra,J. A. Messenger,J. O. Messenger,M. Midei,Matthew R. Miller,David J. Moliterno,K. Momah,M. Mowdy,A. Nahhas,J. Navas,A. Niederman,T. Nygaard,William W. O'Neill,Kunal Patel,S. Pfau,V. Pompili,D. Purdy,B. Reddy,Alan Rees,J. Reiner,A. Riba,E. Rivera,David T. Roberts,A. Rosenblatt,W. Rowe,S. Rowley,D. Rubin,K. Saeian,Frank S. Saltiel,S. Sample,B. Sanchez,I. Sarembock,Jorge F. Saucedo,T. Schreiber,Ranjit Shah,M. Singh,J. Slater,R. Small,C. Staniloae,P. S. Sundram,L. Swenson,G. Symkoviak,K. Tam,A. Taussig,J. Thatcher,P. Tolerico,J. Trippi,S. Turk,K. Van Osdol,R. Vicari,A. Virmani,M. Warner,R. Webel,J. Wertheimer,G. Williams,Jonathan H. Williams,M. Winniford,D. Wohns,D. X.M. Zhao +293 more
TL;DR: In this large clinical trial of patients treated with primary PCI for STEMI, mortality was low and unaffected by administration of pexelizumab, and the composite end points of death, shock, or heart failure were similar.